Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $22.86, significantly above its current trading price of $9.58. Despite some analysts lowering price targets, most maintain buy ratings, while one firm reaffirmed a …